Therapies in acute ischemic stroke have been a matter of clinical and investigational interest in the previous years. The introduction of alteplase (tPA) as a possible acute phase treatment allowed a dramatic improvement in stroke outcomes [1] . However, notwithstanding its merits, the clinical impact caused is significantly impaired due to its narrow therapeutic window, extensive list of contra-indications and limited efficacy in large vessel occlusions.
Up until recently intravenous tPA (IVtPA) was the only option to reperfuse the symptomatic area. Recent work have suggested that endovascular therapies have a role in acute stroke, enhancing the number of patients that may have access to acute phase treatment. Moreover, intra-arterial therapies achieve high levels of hemodynamic and functional efficacy in proximal intracranial occlusionsone of the major limitations of IVtPA [2] [3] [4] [5] [6] . This change in paradigms has urged the revision of local algorithms in stroke units across the globe.
Beholding an acute phase stroke patient with salvageable cerebral tissue, a pragmatic and simplistic approach would present three main clinical scenarios for reperfusion therapies: patients without proximal occlusions of intracranial arteries, and among those with proximal occlusions, patients with and without contra-indication to IVtPA (Figure 1) . For the first clinical scenario IVtPA is highly efficacious, rendering intra-arterial therapies as unnecessary. Moreover, in patients with proximal occlusions and contra-indication to intravenous thrombolysis the answer is straightforward: straight to the catheter lab.
The answer is more troublesome in the presence of a large vessel occlusion without contra-indication to IVtPA. In this scenario IVtPA has reported recanalization rates of 10-30%, depending of clot location and very limited clinical impact [7] . Moreover, in larger thrombus (particularly when longer than 8mm in length) recanalization in the acute stage is almost nonexisting [8] . This has been expressed in all treatment guidelines, recognizing that in this setting all patients should proceed as soon as possible to endovascular treatment and that IVtPA should not delay this procedure [9, 10] . Furthermore, IVtPA has some potentially severe side effects, not only in the ischemic area, but also in remote cerebral areas as well as other organs susceptible to bleeding, frequently in uncompressible locations. There are even reports of higher rates of hemorrhagic complications in patients with proximal occlusions [11] .
It is therefore reasonable to reconsider the role of IVt-PA in acute ischemic stroke in the setting of a large vessel occlusion with the increasing availability of endovascular treatments. Recent retrospective data on this subject confirmed the absence of any therapeutical effect in pretreatment with IVtPA and inconsistent data of hemodynamic outcome. Observational data from 93 patients who presented with an occlusion of the middle cerebral artery suggested a higher rate of successful recanalizations in those treated with concomitant IVtPA and endovascular treatments, as opposed to intra-arterial treatments alone (89.4% vs. 66.7% respectively), suggesting that IVtPA may facilitate mechanical recanalization, however it did not have any significance on early clinical outcome [12] . Other retrospective study described similar rates of good outcome and revascularization of endovascular therapy with and without associated IVtPA [13, 14] . In a recent study with matched pair analysis of patients receiving direct endovascular therapy vs. bridging thrombolysis, similar reperfusion and recanalization rates were observed with lower asymptomatic intracerebral hemorrhage and mortality rates in the direct endovascular therapy group [15] .
A parallel evaluation can be made with another leading cause of death worldwide: ST-segment-elevation myocardial infarction (STEMI). Treatment options have been suffering an evolution similar to acute stroke. Initially, in the 1970-1990s, there was only one therapy approved: intravenous fibrinolysis [16] . However, standard fibrinolytic regimens suffered from several limitations -slow recanalization, low rates of complete recanalization and considerable rates of bleeding complications (much like cerebrovascular events) [17] . In the 2000s, percutaneous coronary intervention (PCI) became an optional therapy for STEMI, with primary PCI showing benefits in recanalization, residual ventricular function and hemorrhagic risk, when performed in the first 120 minutes. Facilitated PCI, i.e. pharmacological reperfusion therapy delivered prior to a PCI showed no clinical benefit in several studies [18] . Nowadays, primary PCI is the preferred strategy if the procedure can be performed by an experienced team and within the first 120 minutes of a STEMI. Only when the delay to PCI is expected to be longer than 120 minutes, fibrinolytic therapies become an option, maintaining however the urgent need of delivering the patient to a PCI capable centre [19] . Naturally, this analogy should be read with caution, considering the significant pathological differences between cardiac and cerebral ischemic events. Nonetheless, it is tempting and reasonable to wonder if there might also be a time frame in which if prompt endo- vascular treatment is deliverable to patients with proximal occlusions, no IVtPA is needed, as opposed to situations where endovascular therapy is not readily accessible and IVtPA should be administered as soon as possible.
All arguments considered, there is in fact the need of randomized clinical trials to reassess the real role of IVtPA in the presence of large vessel occlusion, with endovascular therapies progressively assuming a more central role.
In conclusion, IVtPA will remain the mainstay of acute stroke treatment for all those with clear clinical indications. However, the advent of intra-arterial therapies has had a massive impact on stroke algorithms worldwide. Moreover, the option of going straight to the catheter laboratory with a highly efficient therapy is appealing in the subset of patients with large vessel occlusions and readily accessible neurointervention team, as it would prevent the use of a marginally effective therapy with rare but potentially severe complications.
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